Clinical Trial Detail

NCT ID NCT04093323
Title Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

melanoma

Therapies

alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod

Ipilimumab

unspecified PD-L1 antibody

unspecified PD-1 antibody

Age Groups: senior adult

No variant requirements are available.